The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.90
Bid: 13.80
Ask: 14.00
Change: 0.30 (2.21%)
Spread: 0.20 (1.449%)
Open: 13.60
High: 13.90
Low: 13.60
Prev. Close: 13.60
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Poolbeg hails approval; EDX links with Thermo Fisher

Tue, 21st Nov 2023 14:39

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Poolbeg Pharma PLC - Clinical-stage biopharmaceutical company targeting diseases with a high unmet medical need - Says Japanese Patent Office has granted its Immunomodulator 2 patent application, with the formal grant to be received in due course. The claims cover the pharmaceutical pharmaceutical composition of POLB 001 for treating severe influenza in a hospitalised patient in combination with antiviral compounds. Additionally, Poolbeg adds that it has received the fully granted patent for Immunomodulator 1.

----------

EDX Medical Group PLC - Cambridge, England-based company that develops digital diagnostic products and services for the treatment of cancer, heart disease, and infectious diseases - Enters collaboration agreement with Thermo Fisher Scientific EMEA Ltd. According to the deal, both companies will jointly develop and potentially commercialise a number of proprietary qPCR (real-time polymerase chain reaction) assays - including novel and innovative cancer diagnostic solutions. Thermo Fisher's technologies and information translation systems will be used to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy, and a novel chemotherapy toxicity assay focusing on serious adverse events.

----------

Gelion PLC - London-based Anglo-Australian battery storage company - Signs joint development agreement with Ionblox Inc, a California-based next-generation battery technology company. The agreement aims to deliver safe, high-energy density, lower cost lithium silicon sulfur cells for the global electric vehicle, electrical vertical-takeoff-and-landing and drone markets, before progressing to the stationary energy storage market. Together, Gelion and Ionblox will jointly aim to develop high performance, next-generation LiSiS cells.

----------

Mycelx Technologies Corp - Georgia, US-based clean water and air technology - Receives formal purchase order for the Regen contract, valued at USD5.4 million. The order is for the delivery of a Mycelx-produced water treatment system deploying Regen media. Explains that the system will ensure the unnamed producer is able to reliably discharge clean water overboard in compliance with strict environmental regulations. Expects equipment to be operational in the second half of 2024.

----------

TruFin PLC - London-based financial technology holding company for niche lenders and early payment providers - Says subsidiary, Playstack Ltd, has entered letter of intent to sell intellectual property and assets of its augmented reality and gamification AdTech platform, Interact, to VCI Global Ltd. Notes that whilst transaction terms are yet to be confirmed, any cash consideration is "not expected to be significant" in the context of the wider company. TruFin will provide further updates as appropriate.

----------

UK Oil & Gas PLC - London-based exploration and production company focused on UK and Turkey - Says that the Pinarova joint venture's order of more powerful seven-inch perforating guns arrived in-country last week via airfreight into Istanbul. The new guns will be deployed over the Germik/Hoya section of the site, where strong oil odours at surface were recorded over a 12-hour period during drilling and mobile light oil was recovered from the mud pit.

----------

Dunedin Enterprise Investment Trust PLC - Edinburgh-based UK and overseas companies' investor - Says regulatory approval granted for the realisation of Premier Hytemp, a manufacturer and supplier of engineered metal solutions. The investment in Premier Hytemp is held via DENT's interest in Dunedin Buyout Fund II LP. As of September 30, Dunedin's investment in Premier Hytemp was valued at GBP4.9 million. Following this realisation, it has remaining unlisted investments valued at GBP7.8 million, cash balances of GBP23.3 million, and other net assets of GBP2.9 million. Explains that the board and its advisers are exploring whether to wind-up the company and return cash to shareholders, including the proceeds of the Premier Hytemp realisation, by way of a members' voluntary liquidation. Any such winding-up would require shareholder approval and a further announcement will be made in due course.

----------

Trident Royalties PLC - Mining royalty company - Says all pre-conditions to the Antler Royalty acquisition in the binding acquisition agreement have now been satisfied and that completion has occurred. Previously announced an agreement to buy a 0.9% net smelter return royalty over New World Resources Ltd's Antler copper project in Arizona, US, for a total consideration of AUD11.0 million.

----------

By Holly Beveridge, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
27 May 2022 10:43

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
26 May 2022 16:54

IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

Read more
26 May 2022 10:51

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
12 May 2022 15:35

TRADING UPDATES: Secure Trust lending up; Eurocell sales climb

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2022 20:15

IN BRIEF: Poolbeg hails shareholder confidence as lock-up period ends

Poolbeg Pharma PLC - London-based pharmaceutical company - Confirms proposals have been accepted by distribution in specie shareholders seeking to sell a total of GBP366,000 of Poolbeg shares, representing only 3% of the distribution in specie shares. Says 97% of distribution in specie shareholders have decided to remain invested in Poolbeg following the end of the lock-up period.

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
14 Apr 2022 14:53

Poolbeg granted European patent for antiviral nose spray

(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 21:58

TRADING UPDATES: TruFin raises GBP10 million, Afentra preferred bidder

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
11 Apr 2022 10:57

AIM WINNERS & LOSERS: Mothercare misses payment; Argos licence renewed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:25

IN BRIEF: Poolbeg Pharma starts trading on OTCQB Venture Market

Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Read more
28 Mar 2022 15:10

UK shareholder meetings calendar - next 7 days

Tuesday 29 March 
Impax Asset Management Group PLCAGM
Tekmar Group PLCAGM
Wednesday 30 March 
Brunner Investment Trust PLCAGM
Mediazest PLCAGM
Micro Focus International PLCAGM
Parsley Box Group PLCGM re equity raise
Power Metal Resources PLCGM re carried forward losses
Power Metal Resources PLCAGM
Thursday 31 March 
Pressure Technologies PLCAGM
Red Rock Resources PLCAGM
Aukett Swanke Group PLCAGM
Various Eateries PLCAGM
Toople PLCAGM
BiVictriX Therapeutics PLCAGM
CloudCoCo Group PLCAGM
Friday 1 April 
Gfinity PLCGM re fundraising
River & Mercantile Group PLCAGM
Monday 4 April 
Poolbeg Pharma PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.